Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report
Focus keyword: FDA adverse event reporting hemp 2025
The U.S. Food and Drug Administration (FDA) is significantly enhancing its oversight of hemp-derived cannabinoids like CBD, CBG, and others by incorporating them into federal adverse health event reporting systems. In June 2025, the FDA submitted a proposed update for White House/OMB review to add hemp cannabinoids as selectable product categories in official health event tracking systems—an action with broad implications for cannabis compliance and business operations nationwide (see Marijuana Moment, June 26, 2025; FDA Docket FDA-2024-N-5468 at Regulations.gov). The public comment period closed on July 25, 2025, signaling that these changes could take effect imminently.
For compliance teams, regulatory affairs officers, and cannabis industry executives, preparedness is critical. This transition doesn’t change the legal status of CBD in foods or supplements but creates new regulatory risks and intensifies oversight, especially for brands already marketing hemp cannabinoid products. Here’s what you need to know and how your business should respond.
Since the 2018 Farm Bill, hemp and its derivatives—including CBD—have been federally legal but remain problematic under FDA rules for use in foods and dietary supplements. While the FDA has warned companies not to market hemp cannabinoids as conventional ingestibles, widespread consumer use continues. However, to date, adverse event reporting for hemp cannabinoids has been fragmented and difficult to track.
In June 2025, the FDA advanced a plan to update its adverse event reporting portals—including the Center for Food Safety and Applied Nutrition’s Adverse Event Reporting System (CAERS) and the FDA Adverse Event Reporting System (FAERS)—by adding hemp-derived cannabinoids as explicit product categories. This was transmitted for review (Docket FDA-2024-N-5468) and is expected to go live after the required federal review process.
Key Takeaways:
This action does not legalize new uses of CBD or other cannabinoids, but it will sharply increase scrutiny—from FDA and possibly state partners—on reported product safety issues. Expect new visibility if adverse event clusters arise linked to a brand or category.
For most food and cosmetic companies, serious adverse event reporting is not yet mandatory for hemp cannabinoid products unless they are labeled as dietary supplements (which is still technically not allowed federally for CBD). However, the Dietary Supplement and Nonprescription Drug Consumer Protection Act requires dietary supplement manufacturers to report certain serious adverse events within 15 business days.
If and when FDA formally allows cannabinoids as dietary supplements or expands CAERS/FAERS mandates, companies could face new direct reporting requirements. In the interim, increased data transparency means:
With the new reporting categories, even voluntary or minor complaints may result in FDA scrutiny or requests for follow-up information. Review and upgrade your adverse event and complaint intake SOPs immediately:
If a cluster of adverse events surfaces for a particular product or batch, the FDA may request manufacturing and distribution records in detail. Best practices include:
With increased FDA scrutiny, companies must ensure that all product claims are accurate and compliant. This includes avoiding unapproved health, disease, or drug claims on packaging, websites, or marketing materials. Typical pitfalls include:
Audit your labeling process regularly and correct discrepancies proactively.
States like California, Colorado, and New York maintain their own hemp cannabinoid product and reporting rules. State inspectors may reference FDA adverse event data during compliance audits. Businesses should:
See California's DCC, Colorado MED, and New York OCM for state resources.
The final version of the new adverse event category fields will come after OMB review and possible public feedback from the summer 2025 docket period. Stay current on:
FDA’s signal detection focus means they are actively seeking clusters or novel safety risks. Event triggers may include:
Be prepared for prompt traceability documentation, incident investigation, and, if warranted, voluntary or mandatory recall procedures.
For dietary supplements (though hemp cannabinoids are not yet formally allowed), the serious adverse event reporting requirement is already established under 21 U.S.C. §379aa. Companies must report within 15 business days if a serious health event linked to use arises. This may serve as a template for future regulatory expansion to all hemp cannabinoid products.
For now, voluntary reporting is strongly encouraged, especially if credible health risks are tied to retail products.
Given the FDA’s heightened attention and new surveillance tools, compliance teams should:
Remember, these changes are about consumer safety and market credibility. Companies that are proactive can reduce enforcement risk and maintain reputational trust.
If you experience an adverse health event you associate with a hemp derivative (such as CBD), you can now submit a detailed report directly to FDA’s CAERS or MedWatch portal. With new product categories, your complaints will travel directly to the correct review team. This may enhance safety outcomes and speed regulatory response.
The FDA’s move to include hemp-derived cannabinoids in the official adverse event reporting system is a watershed for regulatory oversight. For cannabis businesses and compliance teams, now is the time to revisit and reinforce your product safety, labeling, and recall systems.
While this doesn’t legalize new CBD pathways or change federal dietary supplement restrictions, it does make visibility—and enforcement—more likely. Prioritize preparedness now to weather any storm of increased attention or regulatory scrutiny.
Stay up to date with federal and state cannabis compliance trends, enforcement actions, and policy updates at CannabisRegulations.ai. Our resources and alerts can help your business remain audit-ready in this rapidly evolving space.